Krystal Biotech Valuation
| KRYS Stock | USD 188.61 0.57 0.30% |
At this time, the firm appears to be overvalued. Krystal Biotech secures a last-minute Real Value of $154.46 per share. The latest price of the firm is $188.61. Our model forecasts the value of Krystal Biotech from analyzing the firm fundamentals such as Current Valuation of 4.86 B, profit margin of 0.31 %, and Return On Equity of 0.1 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Krystal Biotech's valuation include:
Price Book 5.7583 | Enterprise Value | Enterprise Value Ebitda 44.2118 | Price Sales 18.7582 | Forward PE 25.1256 |
Overvalued
Today
Please note that Krystal Biotech's price fluctuation is very steady at this time. Calculation of the real value of Krystal Biotech is based on 3 months time horizon. Increasing Krystal Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Krystal stock is determined by what a typical buyer is willing to pay for full or partial control of Krystal Biotech. Since Krystal Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Krystal Stock. However, Krystal Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 188.61 | Real 154.46 | Target 207.78 | Hype 189.18 | Naive 189.36 |
The intrinsic value of Krystal Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Krystal Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Krystal Biotech helps investors to forecast how Krystal stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Krystal Biotech more accurately as focusing exclusively on Krystal Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Krystal Biotech's intrinsic value based on its ongoing forecasts of Krystal Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Krystal Biotech's closest peers.
Krystal Biotech Cash |
|
Krystal Valuation Trend
Krystal Biotech's real value is important for investors to make better decisions and a more accurate overall view of Krystal Biotech's financial worth over time. Using both Krystal Biotech's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Krystal Biotech Total Value Analysis
Krystal Biotech is now anticipated to have valuation of 4.86 B with market capitalization of 5.45 B, debt of 7.26 M, and cash on hands of 425.56 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Krystal Biotech fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.86 B | 5.45 B | 7.26 M | 425.56 M |
Krystal Biotech Investor Information
About 12.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Krystal Biotech is performing exceptionally good at this time. It has a great odds to report excellent financial results in April.Krystal Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Krystal Biotech has an asset utilization ratio of 27.52 percent. This implies that the Company is making $0.28 for each dollar of assets. An increasing asset utilization means that Krystal Biotech is more efficient with each dollar of assets it utilizes for everyday operations.Krystal Biotech Ownership Allocation
The majority of Krystal Biotech outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Krystal Biotech to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Krystal Biotech. Please pay attention to any change in the institutional holdings of Krystal Biotech as this could imply that something significant has changed or is about to change at the company.Krystal Biotech Profitability Analysis
The company reported the previous year's revenue of 290.51 M. Net Income was 89.16 M with profit before overhead, payroll, taxes, and interest of 270.45 M.About Krystal Biotech Valuation
The stock valuation mechanism determines Krystal Biotech's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Krystal Biotech based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Krystal Biotech. We calculate exposure to Krystal Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Krystal Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 270.5 M | 284 M | |
| Pretax Profit Margin | 0.33 | 0.34 | |
| Operating Profit Margin | 0.23 | 0.24 | |
| Net Profit Margin | 0.31 | 0.32 | |
| Gross Profit Margin | 0.93 | 0.73 |
Krystal Biotech Growth Indicators
Investing in growth stocks can be very risky. If the company such as Krystal Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29.7 M | |
| Quarterly Earnings Growth Y O Y | 4.095 | |
| Forward Price Earnings | 25.1256 |
Krystal Biotech Current Valuation Indicators
Krystal Biotech's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Krystal Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Krystal Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Krystal Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Krystal Biotech's worth.Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.